Search

everythinglearnresearchcommunity

for

Search:↓

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Gefitinib can cause rare scarring hair loss.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

Early intervention and tailored management are crucial for skin side effects in cancer treatments.

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.

Tridax procumbens may boost the immune system.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

TTNPB helps turn stem cells into neural stem cells, improving depression-like behaviors in rats.

PTH-CBD could help prevent and treat hair loss caused by chemotherapy in mice.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

The formula YH0618 can reduce the harmful side effects of the chemotherapy drug Doxorubicin and protect healthy cells.

The study found that analyzing certain cell signaling pathways is not a reliable method to tell apart two types of skin tumors.

Some thymic peptides can increase human hair growth, while others may inhibit it.

TDM10842, a thyroid hormone receptor activator, was found to effectively promote hair growth in mice.

BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

Belatacept may be a promising treatment for alopecia areata.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

A reliable method was developed to measure gemcitabine and olaparib in pancreatic tissue, aiding pancreatic cancer treatment.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.

PT-20 did not significantly improve gray hair repigmentation.